Given that reduced leptin transport to the hypothalamus contributes to central leptin resistance, it is reasonable to speculate that proper application of EGF may offer a potential adjuvant therapy for obesity and its associated leptin resistance. This evidence concerns the gene LEP and obesity due to melanocortin 4 receptor deficiency.